{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:18:57Z","timestamp":1792725537982,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ctro.2026.101121","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:42:26Z","timestamp":1770856946000},"page":"101121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Prognosis of patients with early salvage radiotherapy and low persisting or increasing PSA levels after radical prostatectomy for prostate cancer. A retrospective comparative analysis"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2637-0400","authenticated-orcid":false,"given":"Reinhard","family":"Thamm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Scharl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Gartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk Heinz Gerhard","family":"B\u00f6hmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Siegmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Horsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1042-9006","authenticated-orcid":false,"given":"Benjamin","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2026.101121_b0005","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.euo.2021.01.001","article-title":"Management of persistently elevated prostate-specific antigen after radical prostatectomy: A systematic review of the literature","volume":"4","author":"Ploussard","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ctro.2026.101121_b0010","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1001\/jamaoncol.2025.0110","article-title":"Persistent prostate-specific antigen following radical prostatectomy for prostate cancer and mortality risk","volume":"11","author":"Tilki","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctro.2026.101121_b0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ajur.2022.01.002","article-title":"Clinicopathological and oncological significance of persistent prostate-specific antigen after radical prostatectomy: A systematic review and meta-analysis","volume":"10","author":"Wu","year":"2023","journal-title":"Asian J Urol"},{"key":"10.1016\/j.ctro.2026.101121_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2019.01.048","article-title":"Persistent prostate-specific antigen after radical prostatectomy and its impact on oncologic outcomes","author":"Preisser","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctro.2026.101121_b0025","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.juro.2009.07.022","article-title":"Natural history of persistently elevated prostate specific antigen after radical prostatectomy: Results from the SEARCH database","volume":"182","author":"Moreira","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.ctro.2026.101121_b0030","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ijrobp.2014.09.039","article-title":"Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial","volume":"91","author":"Wiegel","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101121_b0035","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.urology.2023.10.018","article-title":"National long-term survival estimates after radical prostatectomy for prostate cancer","volume":"184","author":"Stensland","year":"2024","journal-title":"Urology"},{"key":"10.1016\/j.ctro.2026.101121_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110476","article-title":"Undetectable PSA predicts outcome after salvage radiotherapy for biochemical recurrence following radical prostatectomy","volume":"200","author":"Scharl","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101121_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110532","article-title":"Prognostic factors in post-prostatectomy salvage radiotherapy setting with and without hormonotherapy: An individual patient data analysis of randomized trials from ICECaP database","volume":"201","author":"Pommier","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101121_b0050","article-title":"Prostate-specific antigen as an ultrasensitive biomarker for patients with early recurrent prostate cancer: How low shall we go?","volume":"12","author":"von Eyben","year":"2024","journal-title":"A Systematic Rev Biomed"},{"key":"10.1016\/j.ctro.2026.101121_b0055","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/bco2.413","article-title":"The accuracy of ultrasensitive PSA in predicting disease progression after radical prostatectomy","volume":"5","author":"Seikkula","year":"2024","journal-title":"BJUI Compass"},{"key":"10.1016\/j.ctro.2026.101121_b0060","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00345-021-03923-y","article-title":"Management of patients with a persistently elevated PSA after radical prostatectomy: A narrative review","volume":"40","author":"Latorzeff","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.ctro.2026.101121_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13050948","article-title":"Prognostic significance of prostate-specific antigen persistence after radical prostatectomy: A systematic review and meta-analysis","volume":"13","author":"Kimura","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctro.2026.101121_b0070","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s12094-021-02700-y","article-title":"Benefits of early salvage therapy on oncological outcomes in high-risk prostate cancer with persistent PSA after radical prostatectomy","volume":"24","author":"Milonas","year":"2022","journal-title":"Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico"},{"key":"10.1016\/j.ctro.2026.101121_b0075","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2024.04.034","article-title":"Risk stratification of patients with recurrence after primary treatment for prostate cancer: A systematic review","volume":"86","author":"Weiner","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctro.2026.101121_b0080","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.radonc.2011.10.024","article-title":"Salvage radiotherapy after prostatectomy - what is the best time to treat?","volume":"103","author":"Siegmann","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101121_b0085","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.22.02489","article-title":"Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death","volume":"41","author":"Tilki","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101121_b0090","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1200\/JCO.2016.67.9647","article-title":"Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy","volume":"34","author":"Tendulkar","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101121_b0095","doi-asserted-by":"crossref","unstructured":"Bottke D, Bartkowiak D, Siegmann A, Thamm R, Bohmer D, Budach V, et al. Effect of early salvage radiotherapy at PSA 0.5 ng\/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer. Prostate cancer and prostatic diseases. 2019;22:344\u20139. https:\/\/doi.org\/10.1038\/s41391-018-0112-3.","DOI":"10.1038\/s41391-018-0112-3"},{"key":"10.1016\/j.ctro.2026.101121_b0100","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.juro.2016.08.106","article-title":"Very early salvage radiotherapy improves distant metastasis-free survival","volume":"197","author":"Abugharib","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.ctro.2026.101121_b0105","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.eururo.2017.06.001","article-title":"Impact of postoperative radiotherapy in men with persistently elevated prostate-specific antigen after radical prostatectomy for prostate cancer: A long-term survival analysis","volume":"72","author":"Gandaglia","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctro.2026.101121_b0110","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on Prostate cancer-2024 update. Part I: Screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctro.2026.101121_b0115","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.ijrobp.2022.09.011","article-title":"GETUG-AFU 22 phase II randomized trial evaluating outcomes of post-operative immediate salvage radiation therapy with or without ADT for patients with persistently elevated PSA level","volume":"114","author":"Latorzeff","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101121_b0120","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2017.35.6_suppl.16","volume":"35","author":"Guerif","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101121_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.02.024","article-title":"Ten-year disease progression and mortality rates in men who experience biochemical recurrence versus persistence after radical prostatectomy and undergo salvage radiation therapy: A post-hoc analysis of RTOG 9601 trial data","volume":"38","author":"Sood","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ctro.2026.101121_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2025.05.013","article-title":"Duration of androgen suppression with postoperative radiotherapy (DADSPORT) for nonmetastatic prostate cancer: A collaborative systematic review and meta-analysis of aggregate data","author":"Burdett","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctro.2026.101121_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.665304","article-title":"Changes of radiation treatment concept based on (68)Ga-PSMA-11-PET\/CT in early PSA-recurrences after radical prostatectomy","volume":"11","author":"Bottke","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctro.2026.101121_b0140","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2967\/jnumed.120.252528","article-title":"Biochemical persistence of prostate-specific antigen after robot-assisted laparoscopic radical prostatectomy: Tumor localizations using PSMA PET\/CT imaging","volume":"62","author":"Meijer","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctro.2026.101121_b0145","article-title":"Detection efficacy of (68)Ga-PSMA-11 PET\/CT in biochemical recurrence of prostate cancer with very low PSA levels: a 7-Year, Two-Center \u201cReal-World\u201d","volume":"15","author":"Burgard","year":"2023","journal-title":"Experience Cancers (Basel)"},{"key":"10.1016\/j.ctro.2026.101121_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110215","article-title":"European association of urology risk stratification predicts outcome in patients receiving PSMA-PET-planned salvage radiotherapy for biochemical recurrence following radical prostatectomy","volume":"194","author":"Scharl","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101121_b0155","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: A systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826000169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826000169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T04:26:06Z","timestamp":1774671966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826000169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"alternative-id":["S2405630826000169"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101121","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognosis of patients with early salvage radiotherapy and low persisting or increasing PSA levels after radical prostatectomy for prostate cancer. A retrospective comparative analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101121"}}